Literature DB >> 35754782

Isolation and Identification of Escherichia coli and Klebsiella pneumoniae Strains Resistant to the Oxyimino-Cephalosporins and the Monobactam by Production of GES Type Extended Spectrum Bêta-Lactamase (ESBL) at Saint Camille Hospital Center in Ouagadougou, Burkina Faso.

Rahimatou Yasmine Wendkuni Tiemtoré1, Amana Mètuor Dabiré1,2, Djénéba Ouermi1, Serge Sougué1, Stéphanie Benao1, Jacques Simporé1.   

Abstract

Background: Bacterial resistance to beta lactamins is a real public health problem as it complicates treatment strategies. Several types of beta lactamase confer this resistance. Numerous studies report a high prevalence of ESBL producers among Gram-negative bacilli. The objective of this work was to identify the presence of the resistance gene GES in strains of E. coli and K. pneumoniae in Burkina Faso.
Methods: During this study 39 strains of E. coli and K. pneumoniae resistant to oxyimino-cephalosporin and monobactam were collected in several samples and analyzed to determine the presence of the beta lactamase resistance gene BlaGES by classic PCR.
Results: In the present study, resistant strains were observed in 21 E. coli and 18 K. pneumoniae. Among producers of ESBL isolates, the presence of the GES gene was detected up to 63% in E. coli and 37% in K pneumoniae.
Conclusion: This study highlighted the presence of the GES gene in strains of E. coli and K. pneumoniae resistant to oxyimino-cephalosporin and monobactam in Burkina Faso. This highlights the presence of new ESBL in Burkina, which is of great interest for the proper care of patients and the control of resistance to antibiotics.
© 2022 Tiemtoré et al.

Entities:  

Keywords:  GES gene; PCR classic; broad-spectrum beta-lactamases

Year:  2022        PMID: 35754782      PMCID: PMC9231687          DOI: 10.2147/IDR.S360945

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.177


  21 in total

1.  Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae.

Authors:  L Poirel; I Le Thomas; T Naas; A Karim; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  The Role of Gram-Negative Bacteria in Urinary Tract Infections: Current Concepts and Therapeutic Options.

Authors:  Payam Behzadi; Edit Urbán; Mária Matuz; Ria Benkő; Márió Gajdács
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Minor extended-spectrum beta-lactamases.

Authors:  T Naas; L Poirel; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

Review 4.  Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.

Authors:  Peter M Hawkey; Roderic E Warren; David M Livermore; Cliodna A M McNulty; David A Enoch; Jonathan A Otter; A Peter R Wilson
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

Review 5.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

Review 6.  Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance.

Authors:  Shiri Navon-Venezia; Kira Kondratyeva; Alessandra Carattoli
Journal:  FEMS Microbiol Rev       Date:  2017-05-01       Impact factor: 16.408

7.  GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem.

Authors:  L Poirel; G F Weldhagen; T Naas; C De Champs; M G Dove; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

8.  GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.

Authors:  Carole Moubareck; Sylvie Brémont; Marie-Christine Conroy; Patrice Courvalin; Thierry Lambert
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  Clinical cases, drug resistance, and virulence genes profiling in Uropathogenic Escherichia coli.

Authors:  Ali Hozzari; Payam Behzadi; Parisa Kerishchi Khiabani; Mohammad Sholeh; Niloofar Sabokroo
Journal:  J Appl Genet       Date:  2020-01-16       Impact factor: 3.240

10.  Mode of delivery and other risk factors for Escherichia coli infections in very low birth weight infants.

Authors:  Agnieszka Chmielarczyk; Jadwiga Wójkowska-Mach; Dorota Romaniszyn; Paweł Adamski; Ewa Helwich; Ryszard Lauterbach; Monika Pobiega; Maria Borszewska-Kornacka; Ewa Gulczyńska; Agnieszka Kordek; Piotr B Heczko
Journal:  BMC Pediatr       Date:  2014-10-18       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.